Association between Plasma Myeloperoxidase and Free 3-Nitrotyrosine Levels in Patients with Coronary Artery Disease
Morteza Pourfarzam, Ahmad Movahedian, Nizal Sarrafzadegan, Gholam Basati, Saed Ziaaldin Samsamshariat
Cardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Clinical Biochemistry, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
Pharmaceutical Sciences Research Centre, Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Pharmaceutical Sciences Research Centre, Department of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran..
DOI: 10.4236/ijcm.2013.43028   PDF    HTML   XML   3,944 Downloads   5,839 Views   Citations


Objective: Myeloperoxidase (MPO) is an inflammatory enzyme that is mainly released by activated neutrophils and monocytes. 3-nitrotyrosine (NT) is a stable inflammatory end product of MPO that is produced through nitrosylation of free and protein-bound tyrosines. Determination of the exact levels of free NT is technically a challenging matter. Also, there is limited information about the relationship between MPO and free NT levels and elevation of them in the plasma of patients with coronary artery disease (CAD). Therefore, we sought to determine the exact level of plasma free NT with a simple and exquisite technique in CAD patients. Methods: This study included 50 stable angina, 50 unstable angina patients, and 50 control subjects. Plasma MPO concentration was measured with an immunoassay method. Plasma free NT level was determined by a modified HPLC-fluorescence method. Lipid profile, high sensitivity C-reactive protein (hsCRP) and other clinical risk factors of patients were also assigned. Results: Plasma level of free NT was efficiently measured by the HPLC-fluorescence method. Plasma levels of MPO and NT were significantly higher in patients with stable and unstable CAD than in control subjects (P < 0.001). There was a significant correlation between the two substances in CAD patients (P < 0.001). Conclusions: We determined plasma free NT levels with a sensitive HPLC-fluorescence method with some modifications in a clinical scale. Plasma levels of MPO and NT were profoundly elevated in CAD patients. The significant relationships of the two substances and elevation of them may have useful clinical implication in patients with stable and unstable CAD.

Share and Cite:

M. Pourfarzam, A. Movahedian, N. Sarrafzadegan, G. Basati and S. Samsamshariat, "Association between Plasma Myeloperoxidase and Free 3-Nitrotyrosine Levels in Patients with Coronary Artery Disease," International Journal of Clinical Medicine, Vol. 4 No. 3, 2013, pp. 158-164. doi: 10.4236/ijcm.2013.43028.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] C. C. Winterbourn and A. J. Kettle, “Biomarkers of Myeloperoxidase-derived Hypochlorous Acid,” Free Radical Biology and Medicine, Vol. 29, No. 4, 2000, pp. 403-409. doi:10.1016/S0891-5849(00)00204-5
[2] A. C. Carr, M. R. McCall and B. Frei, “Oxidation of LDL by Myeloperoxidase and Reactive Nitrogen Species: Reaction Pathways and Antioxidant Protection,” Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 20, No. 7, 2000, pp. 1716-1723. doi:10.1161/01.ATV.20.7.1716
[3] S. J. Klebanoff, “Myeloperoxidase,” Proceedings of the Association of American Physicians, Vo. 111, No. 5, 1999, pp. 383-389.
[4] Z. Prokopowicz, J. Marcinkiewicz, D. R. Katz and B. M. Chain, “Neutrophil Myeloperoxidase: Soldier and Statesman,” Archivum Immunologiae et Therapiae Experimentalis, Vol. 60, No. 1, 2012, pp. 43-54. doi:10.1007/s00005-011-0156-8
[5] I. Mohiuddin, H. Chai, P. H. Lin, A. B. Lumsden, Q. Yao and C. Chen, “Nitrotyrosine and Chlorotyrosine: Clinical Significance and Biological Functions in the Vascular System,” Journal of Surgical Research, Vol. 133, No. 2, 2006, pp. 143-149. doi:10.1016/j.jss.2005.10.008
[6] S. Pennathur, C. Bergt, B. Shao, J. Byun, S. Y. Kassim, P. Singh, P. S. Green, T. O. McDonald, J. Brunzell, A. Chait, J. F. Oram, K. O’brien, R. L. Geary and J. W. Heinecke. “Human Atherosclerotic Intima and Blood of Patients with Established Coronary Artery Disease Contain High Density Lipoprotein Damaged by Reactive Nitrogen Species,” Journal of Biological Chemistry, Vol. 279, No. 41, 2004, pp. 42977-42983. doi:10.1074/jbc.M406762200
[7] M. H. Zou, R. A. Cohen and V. Ullrich, “Peroxynitrite and Vascular Endothelial Dysfunction in Diabetes Mellitus,” Endothelium, Vol. 11, No. 2, 2004, pp. 89-97. doi:10.1080/10623320490482619
[8] L. Zheng, M. Settle, G. Brubaker, D. Schmitt, S. L. Hazen, J. D. Smith and M. Kinter, “Localization of Nitration and Chlorination Sites on Apolipoprotein AI Catalyzed by Myeloperoxidase in Human Atheroma and Associated Oxidative Impairment in ABCA1-Dependent Cholesterol Efflux from Macrophages,” Journal of Biological Chemistry, Vol. 280, No. 1, 2005, pp. 38-47.
[9] E. A. Podrez, D. Schmitt, H. F. Hoff and S. L. Hazen, “Myeloperoxidase-Generated Reactive Nitrogen Species Convert LDL into an Atherogenic Form in Vitro,” Journal of Clinical Investigation, Vo. 103, No. 11, 1999, pp. 1547-1560. doi:10.1172/JCI5549
[10] S. Baldus, J. P. Eiserich, M. L. Brennan, R. M. Jackson, C. B. Alexander and B. A. Freeman, “Spatial Mapping of Pulmonary and Vascular Nitrotyrosine Reveals the Pivotal Role of Myeloperoxidase as a Catalyst for Tyrosine Nitration in Inflammatory Diseases,” Free Radical Biology and Medicine, Vol. 33, No. 7, 2002, pp. 1010-1019. doi:10.1016/S0891-5849(02)00993-0
[11] M. H. Shishehbor, R. J. Aviles, M. L. Brennan, X. Fu, M. Goormastic and G. L. Pearce, “Association of Nitrotyrosine Levels with Cardiovascular Disease and Modulation by Statin Therapy,” Journal of the American Medical Association, Vol. 289, No. 13, 2003, pp. 1675-1680. doi:10.1001/jama.289.13.1675
[12] G. Peluffo and R. Radi, “Biochemistry of Protein Tyrosine Nitration in Cardiovascular Pathology,” Cardiovascular Research, Vol. 75, No. 2, 2007, pp. 291-302. doi:10.1016/j.cardiores.2007.04.024
[13] Y. Kamisaki, K. Wada, K. Nakamoto, Y. Kishimoto, M. Kitano and T. Itoh, “Sensitive Determination of Nitrotyrosine in Human Plasma by Isocratic High-Performance Liquid Chromatography,” Journal of Chromatography B: Biomedical Sciences and Applications, Vol. 685, No. 2, 1996, pp. 343-347. doi:10.1016/S0378-4347(96)00202-2
[14] M. H. Shishehbor, M. L. Brennan, R. J. Aviles, X. Fu, M. S. Penn, D. L. Sprecher and S. L. Hazen, “Statins Promote Potent Systemic Antioxidant Effects through Specific Inflammatory Pathways,” Circulation, Vol. 108, No. 4, 2003, pp. 426-431. doi:10.1161/01.CIR.0000080895.05158.8B
[15] Z. H. Hou, B. Lu, Y. Gao, H. L. Cao, F. F. Yu, N. Jing, et al., “Matrix Metalloproteinase-9 and Myeloperoxidase Levels in Patients with Nonobstructive Coronary Artery Disease Detected by Coronary Computed Tomographic Angiography,” Academic Radiology, Vol. 20, No. 1, 2012, pp. 25-31.
[16] E. A. Podrez, M. Febbraio, N. Sheibani, D. Schmitt, R. L. Silverstein, D. P. Hajjar, P. A. Cohen, W. A. Frazier, H. F. Hoff and S. L. Hazen, “Macrophage Scavenger Receptor CD36 Is the Major Receptor for LDL Modified by Monocyte-generated Reactive Nitrogen Species,” Journal of Clinical Investigation, Vol. 105, No. 8, 2000, pp. 1095-1108. doi:10.1172/JCI8574
[17] M. Febbraio, E. A. Podrez, J. D. Smith, D. P. Hajjar, S. L. Hazen and H. F. Hoff, “Targeted Disruption of the Class B Scavenger Receptor CD36 Protects against Atherosclerotic Lesion Development in Mice,” Journal of Clinical Investigation, Vol. 105, No. 8, 2000, pp. 1049-1056. doi:10.1172/JCI9259
[18] C. D. W. Smythe, V. O. Skinner, K. R. Bruckdorfer, D. O. Haskard and R. C. Landis, “The State of Macrophage Differentiation Determines the TNF [Alpha] Response to Nitrated Lipoprotein Uptake,” Atherosclerosis, Vol. 170, No. 2, 2003, pp. 213-221. doi:10.1016/S0021-9150(03)00285-5
[19] L. Zheng, B. Nukuna, M. L. Brennan, M. Sun, M. Goormastic, M. Settle, D. Schmitt, X. Fu, L. Thomson, P. L. Fox, H. Ischi-ropoulos, J. D. Smith, M. Kinter and S. L. Hazen, “Apolipoprotein AI Is a Selective Target for Myeloperoxidase-Catalyzed Oxidation and Functional Impairment in Subjects with Cardiovascular Disease,” Journal of Clinical Investigation, Vol. 114, No. 4, 2004, pp. 529-541.
[20] D. Tsikas, E. Schwedhelm and J. C. Frolich, “Methodological Considerations on the Detection of 3-Nitrotyrosine in the Cardiovascular System,” Circulation Research, Vol. 90, No. 6, 2002, p. e70. doi:10.1161/01.RES.0000014802.05780.AE
[21] W. Z. Zhang, C. Lang and D. M. Kaye, “Determination of Plasma Free 3-Nitrotyrosine and Tyrosine by Reversed-phase Liquid Chromatography with 4-fluoro-7-Nitrobenzofurazan Derivatization,” Biomedical Chromatography, Vol. 21, No. 3, 2007, pp. 273-278. doi:10.1002/bmc.750
[22] S. Guo, L. Shao, J. Pei, L. Rong, X. Wang and D. Chi, “Determination of Free 3-Nitrotyrosine in Human Plasma Using HPLC Method with Fluorescence Detection,” Chemia Analityczna, Vol. 54, No. 4, 2009, pp. 691-703.
[23] A. S. Pannala, A. R. Mani, J. P. E. Spencer, V. Skinner, K. R. Bruckdorfer, K. P. Moore and C. A. Rice-Evans, “The Effect of Dietary Nitrate on Salivary, Plasma, and Urinary Nitrate Metabolism in Humans,” Free Radical Biology and Medicine, Vol. 34, No. 5, 2003, pp. 576-584. doi:10.1016/S0891-5849(02)01353-9
[24] H. Ryberg and K. Caidahl, “Chromatographic and Mass Spectrometric Methods for Quantitative Determination of 3-Nitrotyrosine in Biological Samples and Their Application to Human Samples,” Journal of Chromatography B, Vol. 851, No. 1-2, 2007, pp. 160-171. doi:10.1016/j.jchromb.2007.02.001
[25] L. L. Wu and J. T. Wu, “Serum 3-Nitrotyrosine May Be Elevated with the Exposure to Acute Inflammatory Risk Factors Such as Unhealthy Diet, Pollutant, Drug and Psychosocial Stress,” Journal of Biomedical Laboratory Sciences, Vol. 19, No. 4, 2007, pp. 113-115.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.